Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study

Background: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function, asthma control, and health-related quality of life compared with placebo in patients with severe, uncontrolled asthma. However, lit-tle is known about the impact of tezepelumab on healthcare utilization (HCU) in these patients. Objective: To evaluate to what extent tezepelumab reduces patients' HCU. Methods: In NAVIGATOR, patients were randomized to receive subcutaneous tezepelumab 210 mg or placebo, every 4 weeks for 52 weeks. For this analysis, the main outcomes of interest were asthma-related HCU. A blinded, systematic analysis of the symptoms and HCU recorded in the investigator-reported narratives describ-ing exacerbation-related hospitalizations was also conducted; the narratives included blinded ratings of event intensity, recorded as mild, moderate, or severe. Results: Recipients of tezepelumab (n = 528) required fewer asthma-related unscheduled specialist visits (teze-pelumab, 285 events; placebo, 406 events), telephone calls with a healthcare provider (tezepelumab, 234; pla-cebo, 599), ambulance transports (tezepelumab, 5; placebo, 22), emergency department visits (without subsequent hospitalization; tezepelumab, 16; placebo, 37), hospitalizations (tezepelumab, 14; placebo, 78), and intensive care days (tezepelumab, 0; placebo, 31) than did recipients of placebo (n = 531). Among patients with asthma exacerbation-related hospitalizations, 38% of those hospitalized and receiving tezepelumab (5/13) had an event rated as severe, compared with 82% of those hospitalized and receiving placebo (32/39). Conclusion: Tezepelumab substantially reduced HCU across all outcomes measured compared with placebo, in addition to the severity of asthma exacerbations requiring hospitalization. Tezepelumab can reduce the overall burden of disease of severe, uncontrolled asthma. Clinical Trial Registration: ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home), identifier: NCT03347279 (c) 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open access arti-cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/)